EMA/485145/2011

# European Medicines Agency decision

P/169/2011

of 8 July 2011

on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys) (EMEA-000298-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/169/2011

of 8 July 2011

on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys) (EMEA-000298-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/94/2010 issued on 2 June 2010,

Having regard to the application submitted by Roche Registration Ltd on 4 March 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 May 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), solution for injection in pre-filled syringe, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

This decision is addressed to Roche Registration Ltd, 6 Falcon Way, Shire Park, AL7 1TW Welwyn Garden City, United Kingdom.

Done at London, 8 July 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)

EMA/PDCO/330160/2011

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000298-PIP01-08-M01

## Scope of the application

**Active substance(s):**

Peginterferon alfa-2a

**Invented name:**

Pegasys

**Condition(s):**

Chronic hepatitis C

Chronic hepatitis B

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Solution for injection in pre-filled syringe

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

Roche Registration Ltd

**Information about the authorised medicinal product:**

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration Ltd submitted to the European Medicines Agency on 4 March 2011 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/94/2010 issued on 2 June 2010.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 23 March 2011.

A meeting with the Paediatric Committee took place on 18 May 2011.

## Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 20 May 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

# 1. Waiver

## *1.1. Condition: Chronic hepatitis C*

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- for solution for injection in pre-filled syringe , subcutaneous use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

## *1.2. Condition: Chronic hepatitis B*

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- for solution for injection in pre-filled syringe , subcutaneous use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

# 2. Paediatric Investigation Plan

## *2.1. Condition: Chronic hepatitis C*

### 2.1.1. Indication(s) targeted by the PIP

Treatment of chronic hepatitis C.

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

### 2.1.3. Pharmaceutical form(s)

Solution for injection in pre-filled syringe (90, 135 and 180 micrograms)

### 2.1.4. Studies

| Area | Number of studies | Description |
|---|---|---|
| Quality | 1 | 1. Development of a 90 µg prefilled syringe for subcutaneous use, with six graduations, to indicate doses of 90, 65, 45, 30, 20, and 10 µg. |
| Non-clinical | | Not applicable. |
| Clinical | 2 | 2. Multicenter, randomised, placebo-controlled safety and efficacy study of ribavirin in children from 5 to less than 18 year old, treated with peginterferon alfa-2a (NV17424, PEDS-C).<br>3. Extrapolation study on the efficacy of peginterferon alfa-2a in paediatric patients with Hepatitis C and 1) have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin, HIV coinfection, or 2) who have HIV coinfection, or 3) who are 3 to less than 5 years of age. |

## *2.2. Condition: Chronic hepatitis B*

### 2.2.1. Indication(s) targeted by the PIP

Treatment of chronic hepatitis B.

### 2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

### 2.2.3. Pharmaceutical form(s)

Solution for injection in pre-filled syringe (90, 135 and 180 micrograms)

### 2.2.4. Studies

| Area | Number of studies | Description |
|---|---|---|
| Quality | 1 | 1. Development of a 90 µg prefilled syringe for subcutaneous use, with six graduations, to indicate doses of 90, 65, 45, 30, 20, and 10 µg (same study as for chronic Hepatitis C). |
| Non-clinical | | Not applicable. |
| Clinical | 2 | 2. Open-label, randomised, superiority study of the efficacy of peginterferon alfa-2a monotherapy versus no treatment in HBeAg positive children with chronic hepatitis B virus infection (YV25718)<br>3. Randomised, HBsAg seroconversion study of peginterferon alfa-2a, alone or in combination with lamivudine, compared to no treatment, in immunotolerant children, from 3 to 16 years, with chronic hepatitis B. |

## 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By March 2014 |
| Deferral for one or more studies contained in the paediatric investigation plan: | No |

# Annex II

# Information about the authorised medicinal product

**Condition(s) and authorised indication(s):**

1. Chronic hepatitis B

   Authorised indications:

   Treatment of HBeAg-positive or HBeAg-negative-chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, increased ALT and histologically verified liver inflammation and/or fibrosis.

2. Chronic hepatitis C

   Authorised indications:

   Treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA, including patients with compensated cirrhosis and/or co-infected with clinically stable HIV.

   The optimal way to use Pegasys in patients with chronic hepatitis C is in combination with ribavirin. The combination of Pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin.

   Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin

| EU Number | (Invented) name | Strength | Pharmaceutical Form | Route of Administration | Packaging | Content (concentration) | Package size |
|---|---|---|---|---|---|---|---|
| EU/1/02/221/001 | Pegasys | 135 µg | Solution for injection | Subcutaneous use | vial (glass) | 1 ml (135 µg/ml) | 1 vial |
| EU/1/02/221/002 | Pegasys | 135 µg | Solution for injection | Subcutaneous use | vial (glass) | 1 ml (135 µg/ml) | 4 vials |
| EU/1/02/221/003 | Pegasys | 180 µg | Solution for injection | Subcutaneous use | vial (glass) | 1 ml (180 µg/ml) | 1 vial |
| EU/1/02/221/004 | Pegasys | 180 µg | Solution for injection | Subcutaneous use | vial (glass) | 1 ml (180 µg/ml) | 4 vials |
| EU/1/02/221/005 | Pegasys | 135 µg | Solution for injection | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (270 µg/ml) | 1 pre-filled syringe + 1 injection needle |
| EU/1/02/221/006 | Pegasys | 135 µg | Solution for injection | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (270 µg/ml) | 4 pre-filled syringes + 4 injection needles |

| EU Number | (Invented) name | Strength | Pharmaceutical Form | Route of Administration | Packaging | Content (concentration) | Package size |
|---|---|---|---|---|---|---|---|
| EU/1/02/221/007 | Pegasys | 180 µg | Solution for injection | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (360 µg/ml) | 1 pre-filled syringe + 1 injection needle |
| EU/1/02/221/008 | Pegasys | 180 µg | Solution for injection | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (360 µg/ml) | 4 pre-filled syringes + 4 injection needles |
| EU/1/02/221/009 | Pegasys | 135 µg | Solution for injection | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (270 µg/ml) | 12 pre-filled syringes + 12 injection needles |
| EU/1/02/221/010 | Pegasys | 180 µg | Solution for injection | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (360 µg/ml) | 12 pre-filled syringes + 12 injection needles |